Navigating the road toward optimal initial therapy for chronic myeloid leukemia
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Hematology
Reference62 articles.
1. Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib
2. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
3. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
4. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
5. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Biological applications of imiquimod analogues: An update (Review);World Academy of Sciences Journal;2023-06-30
2. Tumour‑derived exosomes and their emerging roles in leukaemia (Review);Experimental and Therapeutic Medicine;2023-02-06
3. A series of stable, metastable and unstable salts of Imatinib with improved solubility;Chinese Chemical Letters;2021-10
4. Computational Modeling of Stapled Peptides toward a Treatment Strategy for CML and Broader Implications in the Design of Lengthy Peptide Therapeutics;The Journal of Physical Chemistry B;2018-03-08
5. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms;Leukemia & Lymphoma;2016-05-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3